Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when KYNB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company received formal notice of non-compliance with Nasdaq listing requirements, triggering delisting review process.
Kyntra Bio receives Nasdaq delisting notice for failing $50M asset/revenue requirement
Filed April 9, 2026 · Period ending April 2, 2026 · ~1 min read
Key Changes
-
high
Kyntra Bio received formal notice from Nasdaq on April 2, 2026 that it no longer meets the $50M minimum requirement for total assets and revenue, triggering delisting review. The deficiency stems from FibroGen International revenue being classified as discontinued operations.
Item 3.01 verify on EDGAR → -
high
Company has until May 18, 2026 to submit a compliance plan to Nasdaq. If accepted, Nasdaq may grant up to 180 additional days (until September 29, 2026) to demonstrate compliance. The notice has no immediate effect on current trading status.
Item 3.01 verify on EDGAR → -
medium
As an alternative, Kyntra Bio is considering transferring its listing to the Nasdaq Capital Market, which has lower listing standards and would allow continued Nasdaq trading under less stringent requirements.
Item 3.01 verify on EDGAR →
Summary
Kyntra Bio disclosed it received a deficiency notice from Nasdaq on April 2, 2026 for failing to meet the $50 million minimum threshold for combined total assets and revenue required for Global Select Market listing. The shortfall resulted from the company's FibroGen International revenue being reclassified as discontinued operations in 2024 and 2025, pushing the company below the threshold.
Kyntra also does not meet alternative listing standards based on shareholders' equity or market value. For retail investors, this is a serious warning sign about the company's financial health and market standing, though not an immediate crisis. The stock will continue trading normally while Kyntra works on a solution.
The company has until May 18 to submit a compliance plan and could receive up to six more months to fix the issue if Nasdaq approves their plan. Watch for Kyntra's compliance plan submission in mid-May and whether the company opts to transfer to the Nasdaq Capital Market (a lower tier with easier requirements) or attempts to regain compliance through operational improvements or asset restructuring. Either path signals a company struggling to maintain its market position.
Section-by-Section Diff
Event · Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 2, 2026, Kyntra Bio, Inc. (“Kyntra Bio” or the “Company”) received a letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market notifying us that the Company no longer complies with the Nasdaq Global Select Market continued listing requirement of $50 million in total assets and total revenue for the most recently completed fiscal year (or two of the last three most recently completed fiscal years) per Listing Rule 5450(b) (3) (A).
Kyntra Bio failed to meet Nasdaq's minimum requirement of $50 million in total assets and total revenue. The deficiency stems from FibroGen International revenue being classified as discontinued operations in 2024 and 2025. The company also does not meet alternative listing standards for shareholders' equity or market value of listed securities.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify